This is a preview of subscription content, log in via an institution to check access.
Literatur
Gerendas BS, Prager S, Deak G, Simader C, Lammer J, Waldstein SM, Guerin T, Kundi M, Schmidt-Erfurth UM. Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema. Br J Ophthalmol. 2018;102(2):195–203. https://doi.org/10.1136/bjophthalmol-2017-310483 .
Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA, et al. Optical coherence tomography. Science. 1991;22;254(5035):1178–81.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31.
Ferrara N. Vascular endothelial growth factor. The trigger for neovascularization in the eye. Lab Invest. 1995;72(6):615–8.
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A. RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–25. https://doi.org/10.1016/j.ophtha.2011.01.031 .
Rights and permissions
About this article
Cite this article
MUW researcher of the month. Wien Klin Wochenschr 130, 558–559 (2018). https://doi.org/10.1007/s00508-018-1392-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00508-018-1392-2